$SBFM Cashflow Statement | Understand Stock

$SBFM

$2.65 -$0.35 (11.67%) Close

$SBFM Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash Flows From Operating Activities:
Net (Loss)
Adjustments to reconcile net loss to net cash used in operating activities:
Goodwill impairment
Foreign exchange
Debt release
Depreciation and amortization
Income tax benefit
Disposal of tangible assets
Stock issued for services
Stock issued for payment interest
Loss on debt conversion
Gain on interest and debt forgiveness
Intangible assets impairment
Accounts receivable
Inventory
Prepaid expenses
Right-of-use asset
Accounts Payable & accrued expenses
Deferred tax liability
Lease liability
Earn-out payable
Income tax payable
Interest payable
Net Cash Flows (Used In) Operating Activities

Cash Flows From Investing Activities:
Advances to discontinued operations
Reduction in Right-of-use asset
Nora Pharma acquisition
Cash from Nora Pharma Inc. acquisition
Cash from Nora Pharma acquisition
Purchase of intangible assets
Purchase of equipment

Net Cash Flows (Used In) Investing Activities
Cash Flows From Financing Activities:
Proceeds from public offering net (common stock)
Proceeds from warrant exercises
Purchase of preferred shares
Reduction in lease liability
Payoff of Nora Pharma Inc.’s debt
Proceeds from notes payable
Note payable used to pay fees
Advances to Nora Pharma - pre acquisition
Payments of notes payable
Purchase of treasury stock
Lease liability

Net Cash Flows Provided by Financing Activities
Cash and Cash Equivalents at Beginning of Period
Net (decrease) in cash and cash equivalents
Effect of exchange rate changes on cash
Foreign currency translation adjustment
Cash and Cash Equivalents at End of Period
Supplementary Disclosure of Cash Flow Information:
Cash paid for income taxes
Stock issued for note conversions
Stock issued for acquisition of Nora Pharma, Inc.
Cash paid for interest
Stock issued for acquisition of Nora Pharma
Stock issued for services

Comments